{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:14:29Z","timestamp":1782918869595,"version":"3.54.5"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[1998]]},"DOI":"10.2165\/00063030-199810040-00007","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T00:05:40Z","timestamp":1137629140000},"page":"329-339","source":"Crossref","is-referenced-by-count":25,"title":["Loteprednol Etabonate"],"prefix":"10.1007","volume":"10","author":[{"given":"Stuart","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Goa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":["BioDrugs"],"original-title":[],"language":"en","deposited":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T20:26:00Z","timestamp":1358540760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00063030-199810040-00007"}},"subtitle":["Clinical Potential in the Management of Ocular Inflammation"],"short-title":[],"issued":{"date-parts":[[1998]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.2165\/00063030-199810040-00007","relation":{},"ISSN":["1173-8804"],"issn-type":[{"value":"1173-8804","type":"print"}],"subject":[],"published":{"date-parts":[[1998]]}}}